Ontario nuclear plant to produce material for life-saving cancer treatment
Ontario announced plans Thursday to produce a nu‐ clear medical isotope that forms the essential compo‐ nent in a life-saving treat‐ ment for liver cancer, one of the leading causes of cancer deaths.
The plan involves creating the medical isotope yttrium90 (also known as Y-90) at the Darlington nuclear gener‐ ating station in partnership with a pair of Ottawa-based companies, which transform the radioactive raw material into a cancer-fighting drug called TheraSphere.
The two companies BWXT Medical and Boston
Scientific - already manufac‐ ture the treatment in Ontario but until now, have had to import their supply of iso‐ topes from nuclear reactors outside of Canada.
The deal to produce the isotope at Darlington will ease concerns about access to the raw material for Thera‐ Sphere, which has been provided to more than 100,000 liver cancer patients worldwide, said Peter Patti‐ son, president of Boston Sci‐ entific's interventional on‐ cology franchise in Ottawa.
"Now we have a situation where we have increased ca‐ pacity, increased reliability and increased proximity, so we couldn't ask for a better partner," said Pattison in an interview.
Health Minister Sylvia Jones and Energy Minister Todd Smith announced the deal Thursday afternoon at Ontario's biggest cancer treatment centre, Princess Margaret Hospital in Toronto. Government officials provided CBC News with in‐ formation in advance of the news conference.
The isotope production is to be led by Laurentis Energy Partners, a wholly owned subsidiary of Ontario Power Generation, the provincial Crown corporation that runs Darlington.
"We're using our nuclear power generation in Ontario to produce these life-saving medical isotopes," said Jason Van Wart, president and CEO of Laurentis, in an interview. "While we're seamlessly mak‐ ing electricity, we're also sav‐ ing lives."
Growing use of isotopes in cancer treatment
Various medical isotopes have long been used for di‐ agnosis, particularly in scans of the brain and other or‐ gans. With advances in tech‐ nology, they are increasingly being used in treatment.
Rather than blasting a cancerous tumour with radia‐ tion, running the risk that surrounding healthy cells are killed along with the cancer‐ ous ones, radioactive medical isotopes can be injected to target a tumour directly. The technique is used in treat‐ ment of a range of cancers, including liver and prostate.
Canada was long the wor‐ ld leader in production of the most common medical iso‐ topes.
But since the national re‐ search reactor at Chalk River, Ont. closed in 2018, Canadi‐ an hospitals have been largely reliant on medical iso‐ topes produced in other countries, including Russia and South Africa.
Over the last 15 years, hospitals worldwide have faced at times acute global shortages of some medical isotopes.
WATCH | Treating liver cancer with medical iso‐ topes:
Having a reliable supply of medical isotopes is crucial to diagnosing and treating a whole range of cancers and other diseases, says Dr. Christopher O'Brien, past president of the Canadian As‐ sociation of Nuclear Medi‐ cine.
"Without them there's no ability to assess the state of the disease or the function of the organ," said O'Brien in an interview.
Fresh push for Canadian production
The new plan to produce yt‐ trium-90 in Ontario is part of a recent push to ramp up do‐ mestic production of medical isotopes at Canada's nuclear power stations.
Bruce Power's nuclear plant on the shore of Lake Huron now produces Lutetium-177, a medical iso‐ tope used in treatment of prostate cancer.
Laurentis's system for producing medical isotopes at Darlington began operat‐ ing in December 2022, start‐ ing with molybdenum-99, used widely in diagnostic imaging for detecting cancers and heart disease.
That system at Darlington
will also produce the yttrium90 isotopes used to make TheraSphere, the treatment for liver cancer, the fourthmost common cause of can‐ cer deaths worldwide.
TheraSphere is made up of microscopic glass beads containing the radioactive material. Health Canada ap‐ proved it for use in 2002.
The treatment is created by putting the glass beads in‐ side the nuclear reactor along with a supply of yttri‐ um in its non-radioactive state, known as Y-89. In a process that takes three days, the yttrium atoms pick up an additional neutron to become radioactive Y-90.
The radioactive beads are then transported to BWXT Medical and Boston Scien‐ tific's neighbouring facilities in Ottawa, where the com‐ panies transform them into a medical-grade intravenous serum, before shipping it to hospitals around the world.
"There's quite a number of steps in the process, it's quite technical, and we're very excited that our reactor allows us to be part of that," said Van Wart in an interview with CBC News.
O'Brien, who is not di‐ rectly involved in the com‐ panies producing TheraS‐ phere, said it's important for Canada to have a domestic supply of medical isotopes.
"The further away your supply lines are, the more chances of issues disrupting patient care," he said. "When you're relying on sources from around the world, will the plane show up? Will it get through customs? Will there be a production issue at source?"
O'Brien said treatments like TheraSphere that deliver the radioactive isotopes di‐ rectly to the tumour provide a more targeted attack on the cancerous cells than gen‐ eral radiation and are gener‐ ally better for patients.
"Rather than going through the skin, the bone, the muscles and then to the organ, we are supplying the medical isotope directly to the tumor," he said. "The area that's affected by the medical isotope or the radia‐ tion is much narrower and smaller in size, so there's less collateral damage, if you will, to the surrounding healthy tissues."